Who Owns Exosens Company?

Exosens Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Exosens?

Understanding the ownership structure of a company is crucial for investors and stakeholders alike, especially when dealing with a high-tech innovator like Exosens. The company's journey, marked by an IPO on Euronext Paris in June 2024, has dramatically reshaped its ownership landscape. Exosens, a global leader in detection and imaging technologies, boasts a rich history and a promising future. This article will unravel the intricacies of Exosens SWOT Analysis and its ownership.

From its origins as a Philips subsidiary to its current status as a publicly traded entity, the evolution of Exosens ownership is a fascinating case study. Knowing who owns Exosens provides valuable insights into its strategic direction, financial health, and long-term prospects. With a market capitalization of approximately €2.46 billion as of June 11, 2025, and a reported revenue of €394.1 million in 2024, understanding the Exosens company's ownership is more important than ever. This analysis will explore the Exosens parent company and its key stakeholders, offering a comprehensive view of this dynamic organization, including details about the Exosens headquarters and its leadership.

The story of Exosens ownership begins in 1937, when it started as Hyperelec. Hyperelec was a subsidiary of Philips, operating from Brive-la-Gaillarde, France. This initial phase set the stage for the company's future, with Philips holding complete control.

In 1998, a significant shift occurred as Hyperelec moved away from Philips. This transition led to a merger with Delft Electronic Products (NL) and Burle (USA). This merger was a pivotal moment, transforming the company's structure and setting the foundation for its evolution into Photonis.

Details about the specific equity splits or early investors during these initial changes are not available in the provided data. The move from a Philips subsidiary to an independent entity and then to Photonis shows a shift in Exosens ownership, moving from a single corporate parent to a more diversified structure through mergers.

Early Days

Hyperelec, the predecessor to Exosens, was established in 1937. It was a part of Philips during its early years.

Transition to Photonis

In 1998, Hyperelec merged with Delft Electronic Products and Burle. This merger created Photonis.

Ownership Evolution

The company's ownership changed from being solely under Philips to a structure involving multiple entities.

Ownership Details

Specific information about early shareholders or equity distributions during the transitions is not available.

Foundation of Exosens

The shift from a subsidiary to an independent entity was a key step in the formation of Exosens.

Exosens History

The company's history is marked by significant transitions in ownership and corporate structure.

Key Takeaways

Understanding the evolution of Exosens ownership provides valuable insights into its corporate journey. The shift from a Philips subsidiary to Photonis illustrates the company's changing structure.

• Exosens began as Hyperelec, a Philips subsidiary.
• In 1998, Hyperelec merged with other companies to form Photonis.
• Specific details about early investors are not available.
• The transition highlights the company's changing Exosens ownership structure.

Exosens SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of Exosens ownership has been marked by significant shifts in recent years. Initially, the company, formerly known as Photonis, was acquired by HLD, a French private equity group, in 2021. This acquisition set the stage for a major transformation, culminating in the rebranding to Exosens in 2023. This transition from its previous ownership structure to a private equity-backed model was a pivotal moment in the company's history.

A key milestone in Exosens company's journey was its Initial Public Offering (IPO) on Euronext Paris in June 2024. The IPO, listed under the ticker symbol EXENS, involved both primary and secondary offerings. The primary offering raised approximately €180 million in fresh capital, while the secondary offering, led by selling shareholders including HLD, raised around €170 million. The IPO valued Exosens at approximately €1.016 billion, with shares priced at €20.00 each. Despite the IPO, Groupe HLD remained the majority shareholder.

As of December 10, 2024, the ownership structure showed a diverse mix of shareholders. Private companies held a 53% stake, with HLD Europe S.C.A. as the largest shareholder. Institutional investors held 21%, and the general public held 26%. The French state investment bank, Bpifrance Participations, increased its stake to 7.2% by April 25, 2025, making it the second-largest shareholder after HLD. Key institutional shareholders included CDC Croissance SA and Amundi Asset Management SASU. The CEO, Jérôme Cerisier, held a 1.875% stake. For more insights into the company's strategic direction, you can read about the Growth Strategy of Exosens.

Key Takeaways on Exosens Ownership

The ownership of Exosens has evolved significantly, transitioning from private equity to a publicly listed company.

• HLD remains the majority shareholder.
• Bpifrance Participations is a significant institutional investor.
• The IPO provided fresh capital and increased public ownership.
• Exosens ownership structure includes private companies, institutional investors, and the general public.

Exosens PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of May 23, 2025, the Combined General Meeting of Exosens shareholders was chaired by Jean-Hubert Vial, the Chairman of the Board of Directors. The Board comprises 12 members, with Jean-Hubert Vial as Chair and Jérôme Cerisier as Chief Executive Officer. The roles of Chair and CEO are distinct. Independent directors include Brigitte Geny and Michel Mariton, alongside company representatives like Salim Helou, representing HLD Europe. Understanding the Exosens ownership structure is key to grasping the company's strategic direction.

The structure of the Board of Directors reflects the company's governance model. The presence of independent directors like Brigitte Geny and Michel Mariton, alongside representatives from major shareholders, ensures a balance of perspectives. This structure is crucial for making informed decisions and maintaining stakeholder confidence. To further understand the company's trajectory, consider exploring the Growth Strategy of Exosens.

The voting power at Exosens is significantly influenced by its major shareholders. HLD Europe and Bpifrance Participations held the largest number of voting rights at the May 23, 2025, Combined General Meeting, acting as scrutineers. The General Meeting, with a quorum representing 77.83% of the company's share capital for ordinary resolutions, approved all resolutions. This included the appointment of Bpifrance Investissement as a director, represented by Ms. Dorianne Bonfils. The Board confirmed Bpifrance Investissement's independent director status, following the recommendation of the Nominations and Compensation Committee and an assessment based on the AFEP-MEDEF code criteria. This highlights the importance of understanding who owns Exosens and the implications for corporate governance.

Key Shareholders and Voting Rights

The voting structure is influenced by major shareholders, with HLD Europe and Bpifrance Participations playing key roles.

• HLD Europe and Bpifrance Participations held the largest voting rights.
• The General Meeting approved all resolutions with a 77.83% quorum.
• Bpifrance Investissement was appointed as a director.
• The Board confirmed Bpifrance Investissement's independent status.

Exosens Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent developments at the company, now known as Exosens, have significantly reshaped its ownership and strategic direction. The pivotal acquisition by Groupe HLD in 2021 set the stage for a rebranding and a series of strategic acquisitions. Since December 2022, Exosens has acquired Xenics, Proxivision, El-Mul, and Telops, expanding its technological footprint. Further acquisitions include Noxant, announced in November 2024, and Centronics, acquired in July 2024. These moves reflect a proactive strategy to diversify its portfolio and strengthen its market position. The Marketing Strategy of Exosens has been evolving in tandem with these changes.

A major milestone for Exosens was its Initial Public Offering (IPO) on Euronext Paris in June 2024. This IPO successfully raised approximately €180 million, intended to reduce debt and support growth initiatives. While the IPO brought in new public shareholders, Groupe HLD remains the majority shareholder. As of June 12, 2025, the company's stock price on Euronext Paris was €42.45. The IPO also provided liquidity for existing shareholders, including HLD, marking a significant shift in the company's capital structure.

The ownership landscape of Exosens has seen an increase in institutional involvement. Bpifrance Participations became the second-largest shareholder in April 2025, holding 7.2% of the share capital and voting rights. The company's financial performance for fiscal year 2024 was robust, with revenue reaching €394.1 million, a 35% increase year-over-year, and a net profit of €30.7 million, up 66.7% over 2023. Exosens also declared a cash dividend of €0.10 per share for the 2024 fiscal year, its first dividend payment since the IPO. The company plans to continue its bolt-on acquisition strategy while aiming to balance its revenue mix between Amplification and Detection & Imaging segments, maintaining a leverage ratio of around 2x. Exosens anticipates continued strong performance in 2025, with revenue growth in the high-teens.

Who Owns Exosens?

Groupe HLD remains the majority shareholder, even after the 2024 IPO. Bpifrance Participations is the second-largest shareholder as of April 2025.

Exosens Company Financials

In 2024, Exosens reported revenue of €394.1 million and a net profit of €30.7 million. The company also declared its first dividend.

Exosens Ownership Structure

The ownership structure has evolved with the IPO, introducing public shareholders. Institutional investors are also gaining significant stakes.

Exosens Future Outlook

The company plans to continue acquisitions and anticipates strong revenue growth in 2025, projecting growth in the high-teens.

Exosens Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs